Furthermore, CXCR2 antagonist SB225002 combined with DTX in vivo not only dramatically inhibited the tumor growth but also significantly decreased stemness of breast cancer cells, suggesting CXCR2 may be a potential therapeutic target for breast cancer patients with high expression of CCL20. This evidence concerns the gene CCL20 and breast cancer.